1. 6 versus 12 months of adjuvant trastuzumab for HER2-positive early breast cancer (PERSEPHONE): 4-year disease-free survival results of a randomised phase 3 non-inferiority trial. Issue 10191 (29th June 2019) Authors: Earl, Helena M; Hiller, Louise; Vallier, Anne-Laure; Loi, Shrushma; McAdam, Karen; Hughes-Davies, Luke; Harnett, Adrian N; Ah-See, Mei-Lin; Simcock, Richard; Rea, Daniel; Raj, Sanjay; Woodings, Pamela; Harries, Mark; Howe, Donna; Raynes, Kerry; Higgins, Helen B; Wilcox, Maggie; Plummer, Chris; Ma... Journal: Lancet Issue: Volume 393:Issue 10191(2019) Page Start: 2599 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
2. 6 versus 12 months of adjuvant trastuzumab for HER2-positive early breast cancer (PERSEPHONE): 4-year disease-free survival results of a randomised phase 3 non-inferiority trial. Issue 10191 (29th June 2019) Authors: Earl, Helena M; Hiller, Louise; Vallier, Anne-Laure; Loi, Shrushma; McAdam, Karen; Hughes-Davies, Luke; Harnett, Adrian N; Ah-See, Mei-Lin; Simcock, Richard; Rea, Daniel; Raj, Sanjay; Woodings, Pamela; Harries, Mark; Howe, Donna; Raynes, Kerry; Higgins, Helen B; Wilcox, Maggie; Plummer, Chris; Ma... Journal: Lancet Issue: Volume 393:Issue 10191(2019) Page Start: 2599 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
3. Addition of gemcitabine to paclitaxel, epirubicin, and cyclophosphamide adjuvant chemotherapy for women with early-stage breast cancer (tAnGo): final 10-year follow-up of an open-label, randomised, phase 3 trial. Issue 6 (June 2017) Authors: Earl, Helena M; Hiller, Louise; Howard, Helen C; Dunn, Janet A; Young, Jennie; Bowden, Sarah J; McDermaid, Michelle; Waterhouse, Anna K; Wilson, Gregory; Agrawal, Rajiv; O'Reilly, Susan; Bowman, Angela; Ritchie, Diana M; Goodman, Andrew; Hickish, Tamas; McAdam, Karen; Cameron, David; Dodwell, Dav... Journal: Lancet oncology Issue: Volume 18:Issue 6(2017:Jun.) Page Start: 755 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
4. Residual cancer burden after neoadjuvant chemotherapy and long-term survival outcomes in breast cancer: a multicentre pooled analysis of 5161 patients. Issue 1 (January 2022) Authors: Yau, Christina; Osdoit, Marie; van der Noordaa, Marieke; Shad, Sonal; Wei, Jane; de Croze, Diane; Hamy, Anne-Sophie; Laé, Marick; Reyal, Fabien; Sonke, Gabe S; Steenbruggen, Tessa G; van Seijen, Maartje; Wesseling, Jelle; Martín, Miguel; del Monte-Millán, Maria; López-Tarruella, Sara; Boughey, Ju... Journal: Lancet oncology Issue: Volume 23:Issue 1(2022) Page Start: 149 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
5. The Lancet Breast Cancer Commission: tackling a global health, gender, and equity challenge. Issue 10330 (19th March 2022) Authors: Coles, Charlotte Elizabeth; Anderson, Benjamin O; Cameron, David; Cardoso, Fatima; Horton, Richard; Knaul, Felicia Marie; Mutebi, Miriam; Lee, Naomi; Abraham, Jean E; Anderson, Benjamin O; André, Fabrice; Barrios, Carlos H; Bliss, Judith M; Boughey, Judy C; Cameron, David A; Cardoso, Fatima V; Ca... Journal: Lancet Issue: Volume 399:Issue 10330(2022) Page Start: 1101 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗